Initial Use of the Impella Heart Pump in Israel: Single Center Experience for Safety and 30-Day Outcome - The 65th Annual Conference of the Israel Heart Society & The Israel Society of Cardiothoracic Surgery, 24-25 April 2018

Meir Tabi Cardiology, Shaare Zedek Medical Center, Jerusalem, Israel Yaron Almagor Cardiology, Shaare Zedek Medical Center, Jerusalem, Israel Jonathan Balkin Cardiology, Shaare Zedek Medical Center, Jerusalem, Israel Rami Jubeh Cardiology, Shaare Zedek Medical Center, Jerusalem, Israel David Rosenmann Cardiology, Shaare Zedek Medical Center, Jerusalem, Israel Rivka Farkash Cardiology, Shaare Zedek Medical Center, Jerusalem, Israel Ofra Tzuntz Cardiology, Shaare Zedek Medical Center, Jerusalem, Israel Rafael Wolff Cardiology, Shaare Zedek Medical Center, Jerusalem, Israel

Background: Impella (Abiomed, Danvers, MA) is a percutaneously inserted ventricular assist device (VAD) that pumps blood from the left ventricle into the ascending aorta and systemic circulation. Impella device potentially enables immediate and sustained unloading of the left ventricle while increasing the overall systemic cardiac output to support patients in cardiogenic shock as well as other high risk procedures.

Objective: To investigate the safety of the Impella device implantation and the 30-day outcome in Shaare Zedek Medical Center.

Methods and Results: We have used the Impella CP® in 10 patients. The cases included three Mitra-Clip, three Complex PCI, three cardiogenic shock (including weaning patient from bypass pump) and one case of ventricular tachycardia ablation. All cases considered as “high risk patients / procedures”. Implantation of the Impella CP® was successful in all cases. In nine patients trans-femoral approach was used whereas in one patient trans-sub-clavian was used because of severe peripheral vascular disease. There were no procedural complications or mortality during the procedures. Unfortunately 3 patients died during the hospitalization due to sepsis and multi organ failure.

Conclusions: Our clinical experiences with the Impella heart pump demonstrated that hemodynamic support could be achieved safely, efficiently and effectively in selected patients with extreme high risk profile.